Ercros（0M0E）株式概要Ercros, S.A.は、その子会社とともに、スペイン国内および海外で化学・医薬品を製造・販売している。 詳細0M0E ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長1/6過去の実績0/6財務の健全性2/6配当金0/6報酬収益は年間10.51%増加すると予測されています 同業他社や業界と比較して、良好な取引価格 リスク分析多額の負債を抱えている すべてのリスクチェックを見る0M0E Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€3.4675.4% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-55m990m2016201920222025202620282031Revenue €989.5mEarnings €91.7mAdvancedSet Fair ValueView all narrativesErcros, S.A. 競合他社EssentraSymbol: LSE:ESNTMarket cap: UK£229.7mZotefoamsSymbol: LSE:ZTFMarket cap: UK£209.5mItaconixSymbol: AIM:ITXMarket cap: UK£15.0mSynthomerSymbol: LSE:SYNTMarket cap: UK£127.4m価格と性能株価の高値、安値、推移の概要Ercros過去の株価現在の株価€3.4652週高値€3.4852週安値€2.24ベータ0.191ヶ月の変化1.62%3ヶ月変化1.32%1年変化16.79%3年間の変化8.60%5年間の変化3.59%IPOからの変化38.63%最新ニュースお知らせ • May 28Ercros, S.A., Annual General Meeting, Jun 30, 2026Ercros, S.A., Annual General Meeting, Jun 30, 2026. Location: avenida diagonal 191, barcelona., SpainReported Earnings • May 19First quarter 2026 earnings releasedFirst quarter 2026 results: €0.15 loss per share. Revenue: €154.3m (down 14% from 1Q 2025). Net loss: €13.6m (loss widened 12% from 1Q 2025). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 108 percentage points per year, which is a significant difference in performance.Board Change • May 19Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Carme Moragues Josa was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jan 29Ercros, S.A. to Report Fiscal Year 2025 Results on Feb 27, 2026Ercros, S.A. announced that they will report fiscal year 2025 results on Feb 27, 2026Buy Or Sell Opportunity • Dec 17Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 27% to €3.41. The fair value is estimated to be €2.83, however this is not to be taken as a sell recommendation but rather should be used as a guide only.Reported Earnings • Nov 12Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: €161.5m (up 4.3% from 3Q 2024). Net loss: €12.0m (loss widened 30% from 3Q 2024). Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom.最新情報をもっと見るRecent updatesお知らせ • May 28Ercros, S.A., Annual General Meeting, Jun 30, 2026Ercros, S.A., Annual General Meeting, Jun 30, 2026. Location: avenida diagonal 191, barcelona., SpainReported Earnings • May 19First quarter 2026 earnings releasedFirst quarter 2026 results: €0.15 loss per share. Revenue: €154.3m (down 14% from 1Q 2025). Net loss: €13.6m (loss widened 12% from 1Q 2025). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 108 percentage points per year, which is a significant difference in performance.Board Change • May 19Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Carme Moragues Josa was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jan 29Ercros, S.A. to Report Fiscal Year 2025 Results on Feb 27, 2026Ercros, S.A. announced that they will report fiscal year 2025 results on Feb 27, 2026Buy Or Sell Opportunity • Dec 17Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 27% to €3.41. The fair value is estimated to be €2.83, however this is not to be taken as a sell recommendation but rather should be used as a guide only.Reported Earnings • Nov 12Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: €161.5m (up 4.3% from 3Q 2024). Net loss: €12.0m (loss widened 30% from 3Q 2024). Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom.Board Change • Nov 11Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 5 highly experienced directors. Proprietary Director Joan Galofre was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 12Ercros, S.A. to Report Q3, 2025 Results on Nov 11, 2025Ercros, S.A. announced that they will report Q3, 2025 results on Nov 11, 2025お知らせ • Aug 12Esseco Industrial S.P.A. cancelled the acquisition of Ercros, S.A. (BME:ECR).Esseco Industrial S.P.A. made an offer to acquire Ercros, S.A. (BME:ECR) for approximately €350 million on June 19, 2024. A cash consideration valued at €3.84 per share will be paid by Esseco Industrial S.P.A. Under the terms, the compensation will be in cash and amounts to a maximum total of €351.1 million. Esseco will promote talent retention and maintain Ercros' headquarters in Barcelona. The offer price has been calculated on the basis that if the target company makes any distribution of dividends, the offer price would be reduced by an amount equivalent to the gross amount per share of such distribution. The offer is addressed to the entire share capital of Ercros and is subject to a minimum acceptance condition of 75% as well as to the customary administrative and governmental authorisations for this type of transactions, which will be described in detail in the prospectus that will be made available to shareholders upon completion of its processing by the Comisión Nacional del Mercado de Valores. As of June 28, 2024, the general meeting has approved all the resolution proposals presented by the board of directors of Ercros. The management body of the Bidder approved by unanimity of all its directors on 19 June 2024 launching the Offer, subject to obtaining the necessary financing commitments to ensure the Offeror’s full payment of the cash consideration. As of July 11, 2024, In relation to the takeover bid presented by Bondalti for the capital of Ercros, the Portuguese company states that, as a result of the dividend charged to the 2023 profit of gross €0.096 per share that Ercros paid to its shareholders on July 10, 2024, Bidder has adjusted the Offer price, has deducted this amount from the takeover price and, after rounding the resulting figure, the price becomes €3.745 per share. The National Markets Commission (CNMC) has begun phase two of its analysis of Esseco's takeover bid for Ercros. The company has notified the National Securities Market Commission (CNMV), the stock market supervisor, of this step and has recalled that the CNMC's lack of opposition to the operation is one of the conditions to which the "effectiveness" of the offer is subject. The board of directors and the management team of Ercros will continue to manage the Company's business diligently in the ordinary course of its activity, ensuring the corporate interest and with full respect for the obligations established by the applicable regulations, for which it has the advice from Evercore Partners International LLP, as financial advisor, and from Uría Menéndez Abogados, S.L.P., as legal advisor. Esseco has been advised by J.P. Morgan as financial advisor and Gianni & Origoni as well as Javier Carvajal, Javier Gómez and Teresa Méndez of Pérez-Llorca Abogados, S.L.P. as legal counsels. Esseco Industrial S.P.A. cancelled the acquisition of Ercros, S.A. (BME:ECR) on August 11, 2025.Reported Earnings • Jul 30Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €180.0m (up 1.4% from 2Q 2024). Net loss: €17.1m (loss widened €15.5m from 2Q 2024). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom.New Risk • May 15New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 5.8% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.8% operating cash flow to total debt). Earnings have declined by 13% per year over the past 5 years. Minor Risk Paying a dividend despite having no free cash flows.Reported Earnings • May 15First quarter 2025 earnings releasedFirst quarter 2025 results: €0.13 loss per share. Revenue: €184.5m (up 1.0% from 1Q 2024). Net loss: €12.2m (down 499% from profit in 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 95 percentage points per year, which is a significant difference in performance.お知らせ • May 14Ercros, S.A., Annual General Meeting, Jun 26, 2025Ercros, S.A., Annual General Meeting, Jun 26, 2025. Location: avenida diagonal 514, planta 6., barcelona Spainお知らせ • Apr 16Ercros, S.A. to Report Q1, 2025 Results on May 13, 2025Ercros, S.A. announced that they will report Q1, 2025 results on May 13, 2025お知らせ • Mar 05Ercros, S.A. to Report Fiscal Year 2024 Final Results on Mar 31, 2025Ercros, S.A. announced that they will report fiscal year 2024 final results at 5:30 PM, Romance Standard Time on Mar 31, 2025Reported Earnings • Feb 27Full year 2024 earnings releasedFull year 2024 results: Revenue: €699.0m (down 3.8% from FY 2023). Net loss: €11.7m (down 141% from profit in FY 2023).お知らせ • Jan 28Ercros, S.A. to Report Second Half, 2024 Results on Feb 25, 2025Ercros, S.A. announced that they will report second half, 2024 results on Feb 25, 2025Reported Earnings • Nov 08Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: €173.5m (up 12% from 3Q 2023). Net loss: €9.20m (loss narrowed 15% from 3Q 2023). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 6.6% decline forecast for the Chemicals industry in the United Kingdom.Reported Earnings • Aug 01Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €188.4m (down 11% from 2Q 2023). Net loss: €1.66m (down 143% from profit in 2Q 2023). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.Upcoming Dividend • Jul 01Upcoming dividend of €0.078 per shareEligible shareholders must have bought the stock before 08 July 2024. Payment date: 10 July 2024. Payout ratio is a comfortable 23% and this is well supported by cash flows. Trailing yield: 2.5%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (3.3%).Reported Earnings • May 03First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: €0.033. Revenue: €188.7m (down 14% from 1Q 2023). Net income: €3.05m (down 78% from 1Q 2023). Profit margin: 1.6% (down from 6.4% in 1Q 2023). Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 2.7% decline forecast for the Chemicals industry in the United Kingdom.Valuation Update With 7 Day Price Move • Mar 05Investor sentiment improves as stock rises 35%After last week's 35% share price gain to €3.42, the stock trades at a forward P/E ratio of 13x. Average trailing P/E is 17x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 41% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €2.71 per share.Buy Or Sell Opportunity • Mar 05Now 26% overvalued after recent price riseOver the last 90 days, the stock has risen 40% to €3.42. The fair value is estimated to be €2.71, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 4.8% per annum. Earnings are also forecast to grow by 7.6% per annum over the same time period.お知らせ • Mar 05Bondalti Ibérica launched a public takeover offer to acquire Ercros, S.A. (BME:ECR) for €340 million .Bondalti Ibérica launched a public takeover offer to acquire Ercros, S.A. (BME:ECR) for €340 million on March 5, 2024. Offer price is €3.6 per share. The transaction is still conditional on the acceptance of more than 75% of the capital and the obtaining of all relevant regulatory and governmental approvals.Reported Earnings • Mar 01Full year 2023 earnings releasedFull year 2023 results: Revenue: €757.6m (down 26% from FY 2022). Net income: €28.8m (down 59% from FY 2022). Profit margin: 3.8% (down from 6.9% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 3.3% decline forecast for the Chemicals industry in the United Kingdom.お知らせ • Dec 01+ 2 more updatesErcros, S.A. to Report Q3, 2024 Results on Nov 15, 2024Ercros, S.A. announced that they will report Q3, 2024 results on Nov 15, 2024Valuation Update With 7 Day Price Move • Nov 13Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €2.47, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 19x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €2.39 per share.New Risk • Nov 08New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.8% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (4.2% net profit margin).お知らせ • Oct 18Ercros, S.A. to Report Q3, 2023 Results on Nov 08, 2023Ercros, S.A. announced that they will report Q3, 2023 results on Nov 08, 2023New Risk • Jul 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.2% Last year net profit margin: 8.3% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (4.2% net profit margin).Reported Earnings • Jul 27Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €222.4m (down 22% from 2Q 2022). Net income: €3.81m (down 87% from 2Q 2022). Profit margin: 1.7% (down from 10% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is expected to fall by 1.4% p.a. on average during the next 3 years compared to a 6.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. Proprietary Director Joan Galofre was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jun 23+ 1 more updateErcros, S.A. to Report First Half, 2023 Results on Aug 31, 2023Ercros, S.A. announced that they will report first half, 2023 results on Aug 31, 2023Upcoming Dividend • Jun 19Upcoming dividend of €0.12 per share at 4.8% yieldEligible shareholders must have bought the stock before 26 June 2023. Payment date: 28 June 2023. Payout ratio is a comfortable 21% and this is well supported by cash flows. Trailing yield: 4.8%. Lower than top quartile of British dividend payers (5.9%). Higher than average of industry peers (2.7%).お知らせ • May 04Ercros, S.A., Annual General Meeting, Jun 15, 2023Ercros, S.A., Annual General Meeting, Jun 15, 2023, at 12:00 Central European Standard Time. Location: Uría Menéndez Auditorium, Avenida Diagonal 514, 6th floor Barcelona Spain Agenda: To consider financial statements and directors' report; to consider statement of non-financial information of the Company and its consolidated Group for the year ended 31 December 2022; to consider Re-election of Ernst & Young, S.L. as the auditor.Buying Opportunity • May 03Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 2.6%. The fair value is estimated to be €4.62, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 48%. For the next 3 years, revenue is forecast to decline by 5.4% per annum. Earnings is also forecast to decline by 12% per annum over the same time period.Reported Earnings • Feb 24Full year 2022 earnings released: EPS: €0.64 (vs €0.43 in FY 2021)Full year 2022 results: EPS: €0.64 (up from €0.43 in FY 2021). Revenue: €1.02b (up 28% from FY 2021). Net income: €70.6m (up 63% from FY 2021). Profit margin: 6.9% (up from 5.4% in FY 2021). The increase in margin was driven by higher revenue. Revenue is expected to decline by 8.9% p.a. on average during the next 2 years, while revenues in the Chemicals industry in the United Kingdom are expected to grow by 1.7%. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 30Ercros, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023Ercros, S.A. announced that they will report fiscal year 2022 results on Feb 28, 2023Buying Opportunity • Nov 16Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 7.3%. The fair value is estimated to be €3.97, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 36%. Revenue is forecast to decline by 13% in 2 years. Earnings is forecast to decline by 40% in the next 2 years.Buying Opportunity • Nov 10Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 4.2%. The fair value is estimated to be €4.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 36%. Revenue is forecast to decline by 13% in 2 years. Earnings is forecast to decline by 40% in the next 2 years.Reported Earnings • Jul 30Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €297.7m (up 50% from 2Q 2021). Net income: €29.1m (up 152% from 2Q 2021). Profit margin: 9.8% (up from 5.8% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is expected to shrink by 3.5% compared to a 15% decline forecast for the industry in the United Kingdom.Buying Opportunity • Jul 28Now 21% undervaluedOver the last 90 days, the stock is up 11%. The fair value is estimated to be €4.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.9% over the last 3 years. Earnings per share has grown by 26%. Revenue is forecast to decline by 5.0% in 2 years. Earnings is forecast to decline by 3.9% in the next 2 years.Buying Opportunity • Jul 01Now 21% undervaluedOver the last 90 days, the stock is up 20%. The fair value is estimated to be €4.64, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.9% over the last 3 years. Earnings per share has grown by 26%. Revenue is forecast to decline by 5.0% in 2 years. Earnings is forecast to decline by 3.9% in the next 2 years.Upcoming Dividend • Jun 13Upcoming dividend of €0.069 per shareEligible shareholders must have bought the stock before 20 June 2022. Payment date: 22 June 2022. Trailing yield: 2.4%. Lower than top quartile of British dividend payers (4.9%). Lower than average of industry peers (3.0%).Buying Opportunity • May 06Now 20% undervaluedOver the last 90 days, the stock is up 9.1%. The fair value is estimated to be €4.15, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 6.1%. Revenue is forecast to decline by 7.5% in 2 years. Earnings is forecast to decline by 13% in the next 2 years.Buying Opportunity • Mar 23Now 21% undervaluedOver the last 90 days, the stock is up 1.8%. The fair value is estimated to be €3.88, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 6.1% per annum over the last 3 years.Buying Opportunity • Mar 03Now 22% undervaluedOver the last 90 days, the stock is up 8.9%. The fair value is estimated to be €3.97, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 6.1% per annum over the last 3 years.Reported Earnings • Nov 14Third quarter 2021 earnings releasedThe company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €210.9m (up 56% from 3Q 2020). Net income: €5.90m (up €5.70m from 3Q 2020). Profit margin: 2.8% (up from 0.1% in 3Q 2020). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • May 10Investor sentiment improved over the past weekAfter last week's 16% share price gain to €3.12, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 26x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 24% over the past three years.Reported Earnings • Mar 02Full year 2020 earnings released: EPS €0.061 (vs €0.29 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €585.3m (down 13% from FY 2019). Net income: €6.26m (down 80% from FY 2019). Profit margin: 1.1% (down from 4.6% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.Analyst Estimate Surprise Post Earnings • Mar 02Revenue beats expectationsRevenue exceeded analyst estimates by 3.0%. Over the next year, revenue is forecast to grow 5.8% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom.Is New 90 Day High Low • Feb 16New 90-day high: €2.51The company is up 18% from its price of €2.14 on 17 November 2020. The British market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period.Valuation Update With 7 Day Price Move • Nov 26Market bids up stock over the past weekAfter last week's 15% share price gain to €2.39, the stock is trading at a trailing P/E ratio of 10.2x, up from the previous P/E ratio of 8.8x. This compares to an average P/E of 37x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years were flat.Is New 90 Day High Low • Nov 24New 90-day high: €2.19The company is up 6.0% from its price of €2.07 on 25 August 2020. The British market is also up 6.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Chemicals industry, which is up 5.0% over the same period.Is New 90 Day High Low • Nov 02New 90-day low: €1.75The company is down 5.0% from its price of €1.84 on 04 August 2020. The British market is down 6.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 2.0% over the same period.株主還元0M0EGB ChemicalsGB 市場7D-0.1%-2.5%0.8%1Y16.8%5.9%19.0%株主還元を見る業界別リターン: 0M0E過去 1 年間で5.9 % の収益を上げたUK Chemicals業界を上回りました。リターン対市場: 0M0Eは、過去 1 年間で19 % のリターンを上げたUK市場を下回りました。価格変動Is 0M0E's price volatile compared to industry and market?0M0E volatility0M0E Average Weekly Movement0.8%Chemicals Industry Average Movement7.0%Market Average Movement5.5%10% most volatile stocks in GB Market10.9%10% least volatile stocks in GB Market3.0%安定した株価: 0M0E 、 UK市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 0M0Eの 週次ボラティリティ ( 1% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト18171,329Joao Maria Guimaraes Jose Mellowww.ercros.esErcros, S.A.は、子会社とともにスペイン国内および海外で化学品および医薬品の製造・販売を行っている。3つのセグメントで事業を展開：塩素誘導体、中間化学品、医薬品。アンモニア、苛性ソーダとカリ、塩素クロロイソシアヌレート、ジクロロエタン、エルクロスビオ、塩酸、過酸化水素、ポリ塩化ビニル、炭酸カリウム、PVC化合物、塩素酸ナトリウム、亜塩素酸ナトリウム、次亜塩素酸ナトリウム、硫酸、塩化ビニルを提供している。また、ジペンタエリスリトール、エルクロスグリーン＋樹脂、ホルムアルデヒド、メタノール、成形コンパウンド、パラホルムアルデヒド、ペンタエリスリトール、ギ酸ナトリウムも提供している。また、アムロジピンベシル酸塩、アジスロマイシン、クラリスロマイシン、エリスロマイシン、ファモチジン、ホスホマイシン、フシジン酸などのジェネリック医薬品原薬や、抗生物質、抗高血圧薬、抗潰瘍薬の受託製造も行っている。製品を輸出している。旧社名はS.A. Crosで、1989年6月に社名をErcros, S.A.に変更。Ercros,S.A.は1817年に設立され、スペインのバルセロナに本社を置いている。もっと見るErcros, S.A. 基礎のまとめErcros の収益と売上を時価総額と比較するとどうか。0M0E 基礎統計学時価総額€316.37m収益（TTM）-€55.04m売上高(TTM)€600.27m0.5xP/Sレシオ-5.7xPER（株価収益率0M0E は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計0M0E 損益計算書（TTM）収益€600.27m売上原価€426.69m売上総利益€173.58mその他の費用€228.63m収益-€55.04m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.60グロス・マージン28.92%純利益率-9.17%有利子負債／自己資本比率71.1%0M0E の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/25 07:50終値2026/06/25 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ercros, S.A. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Bruno BessaCaixa Banco BPIAlfredo Echevarria OteguiLighthouse-IEAF Servicios de AnalisisPablo RiveraLighthouse-IEAF Servicios de Analisis
お知らせ • May 28Ercros, S.A., Annual General Meeting, Jun 30, 2026Ercros, S.A., Annual General Meeting, Jun 30, 2026. Location: avenida diagonal 191, barcelona., Spain
Reported Earnings • May 19First quarter 2026 earnings releasedFirst quarter 2026 results: €0.15 loss per share. Revenue: €154.3m (down 14% from 1Q 2025). Net loss: €13.6m (loss widened 12% from 1Q 2025). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 108 percentage points per year, which is a significant difference in performance.
Board Change • May 19Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Carme Moragues Josa was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 29Ercros, S.A. to Report Fiscal Year 2025 Results on Feb 27, 2026Ercros, S.A. announced that they will report fiscal year 2025 results on Feb 27, 2026
Buy Or Sell Opportunity • Dec 17Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 27% to €3.41. The fair value is estimated to be €2.83, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
Reported Earnings • Nov 12Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: €161.5m (up 4.3% from 3Q 2024). Net loss: €12.0m (loss widened 30% from 3Q 2024). Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom.
お知らせ • May 28Ercros, S.A., Annual General Meeting, Jun 30, 2026Ercros, S.A., Annual General Meeting, Jun 30, 2026. Location: avenida diagonal 191, barcelona., Spain
Reported Earnings • May 19First quarter 2026 earnings releasedFirst quarter 2026 results: €0.15 loss per share. Revenue: €154.3m (down 14% from 1Q 2025). Net loss: €13.6m (loss widened 12% from 1Q 2025). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 108 percentage points per year, which is a significant difference in performance.
Board Change • May 19Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Carme Moragues Josa was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 29Ercros, S.A. to Report Fiscal Year 2025 Results on Feb 27, 2026Ercros, S.A. announced that they will report fiscal year 2025 results on Feb 27, 2026
Buy Or Sell Opportunity • Dec 17Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 27% to €3.41. The fair value is estimated to be €2.83, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
Reported Earnings • Nov 12Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: €161.5m (up 4.3% from 3Q 2024). Net loss: €12.0m (loss widened 30% from 3Q 2024). Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom.
Board Change • Nov 11Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 5 highly experienced directors. Proprietary Director Joan Galofre was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 12Ercros, S.A. to Report Q3, 2025 Results on Nov 11, 2025Ercros, S.A. announced that they will report Q3, 2025 results on Nov 11, 2025
お知らせ • Aug 12Esseco Industrial S.P.A. cancelled the acquisition of Ercros, S.A. (BME:ECR).Esseco Industrial S.P.A. made an offer to acquire Ercros, S.A. (BME:ECR) for approximately €350 million on June 19, 2024. A cash consideration valued at €3.84 per share will be paid by Esseco Industrial S.P.A. Under the terms, the compensation will be in cash and amounts to a maximum total of €351.1 million. Esseco will promote talent retention and maintain Ercros' headquarters in Barcelona. The offer price has been calculated on the basis that if the target company makes any distribution of dividends, the offer price would be reduced by an amount equivalent to the gross amount per share of such distribution. The offer is addressed to the entire share capital of Ercros and is subject to a minimum acceptance condition of 75% as well as to the customary administrative and governmental authorisations for this type of transactions, which will be described in detail in the prospectus that will be made available to shareholders upon completion of its processing by the Comisión Nacional del Mercado de Valores. As of June 28, 2024, the general meeting has approved all the resolution proposals presented by the board of directors of Ercros. The management body of the Bidder approved by unanimity of all its directors on 19 June 2024 launching the Offer, subject to obtaining the necessary financing commitments to ensure the Offeror’s full payment of the cash consideration. As of July 11, 2024, In relation to the takeover bid presented by Bondalti for the capital of Ercros, the Portuguese company states that, as a result of the dividend charged to the 2023 profit of gross €0.096 per share that Ercros paid to its shareholders on July 10, 2024, Bidder has adjusted the Offer price, has deducted this amount from the takeover price and, after rounding the resulting figure, the price becomes €3.745 per share. The National Markets Commission (CNMC) has begun phase two of its analysis of Esseco's takeover bid for Ercros. The company has notified the National Securities Market Commission (CNMV), the stock market supervisor, of this step and has recalled that the CNMC's lack of opposition to the operation is one of the conditions to which the "effectiveness" of the offer is subject. The board of directors and the management team of Ercros will continue to manage the Company's business diligently in the ordinary course of its activity, ensuring the corporate interest and with full respect for the obligations established by the applicable regulations, for which it has the advice from Evercore Partners International LLP, as financial advisor, and from Uría Menéndez Abogados, S.L.P., as legal advisor. Esseco has been advised by J.P. Morgan as financial advisor and Gianni & Origoni as well as Javier Carvajal, Javier Gómez and Teresa Méndez of Pérez-Llorca Abogados, S.L.P. as legal counsels. Esseco Industrial S.P.A. cancelled the acquisition of Ercros, S.A. (BME:ECR) on August 11, 2025.
Reported Earnings • Jul 30Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €180.0m (up 1.4% from 2Q 2024). Net loss: €17.1m (loss widened €15.5m from 2Q 2024). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom.
New Risk • May 15New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 5.8% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.8% operating cash flow to total debt). Earnings have declined by 13% per year over the past 5 years. Minor Risk Paying a dividend despite having no free cash flows.
Reported Earnings • May 15First quarter 2025 earnings releasedFirst quarter 2025 results: €0.13 loss per share. Revenue: €184.5m (up 1.0% from 1Q 2024). Net loss: €12.2m (down 499% from profit in 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 95 percentage points per year, which is a significant difference in performance.
お知らせ • May 14Ercros, S.A., Annual General Meeting, Jun 26, 2025Ercros, S.A., Annual General Meeting, Jun 26, 2025. Location: avenida diagonal 514, planta 6., barcelona Spain
お知らせ • Apr 16Ercros, S.A. to Report Q1, 2025 Results on May 13, 2025Ercros, S.A. announced that they will report Q1, 2025 results on May 13, 2025
お知らせ • Mar 05Ercros, S.A. to Report Fiscal Year 2024 Final Results on Mar 31, 2025Ercros, S.A. announced that they will report fiscal year 2024 final results at 5:30 PM, Romance Standard Time on Mar 31, 2025
Reported Earnings • Feb 27Full year 2024 earnings releasedFull year 2024 results: Revenue: €699.0m (down 3.8% from FY 2023). Net loss: €11.7m (down 141% from profit in FY 2023).
お知らせ • Jan 28Ercros, S.A. to Report Second Half, 2024 Results on Feb 25, 2025Ercros, S.A. announced that they will report second half, 2024 results on Feb 25, 2025
Reported Earnings • Nov 08Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: €173.5m (up 12% from 3Q 2023). Net loss: €9.20m (loss narrowed 15% from 3Q 2023). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 6.6% decline forecast for the Chemicals industry in the United Kingdom.
Reported Earnings • Aug 01Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €188.4m (down 11% from 2Q 2023). Net loss: €1.66m (down 143% from profit in 2Q 2023). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
Upcoming Dividend • Jul 01Upcoming dividend of €0.078 per shareEligible shareholders must have bought the stock before 08 July 2024. Payment date: 10 July 2024. Payout ratio is a comfortable 23% and this is well supported by cash flows. Trailing yield: 2.5%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (3.3%).
Reported Earnings • May 03First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: €0.033. Revenue: €188.7m (down 14% from 1Q 2023). Net income: €3.05m (down 78% from 1Q 2023). Profit margin: 1.6% (down from 6.4% in 1Q 2023). Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 2.7% decline forecast for the Chemicals industry in the United Kingdom.
Valuation Update With 7 Day Price Move • Mar 05Investor sentiment improves as stock rises 35%After last week's 35% share price gain to €3.42, the stock trades at a forward P/E ratio of 13x. Average trailing P/E is 17x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 41% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €2.71 per share.
Buy Or Sell Opportunity • Mar 05Now 26% overvalued after recent price riseOver the last 90 days, the stock has risen 40% to €3.42. The fair value is estimated to be €2.71, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 4.8% per annum. Earnings are also forecast to grow by 7.6% per annum over the same time period.
お知らせ • Mar 05Bondalti Ibérica launched a public takeover offer to acquire Ercros, S.A. (BME:ECR) for €340 million .Bondalti Ibérica launched a public takeover offer to acquire Ercros, S.A. (BME:ECR) for €340 million on March 5, 2024. Offer price is €3.6 per share. The transaction is still conditional on the acceptance of more than 75% of the capital and the obtaining of all relevant regulatory and governmental approvals.
Reported Earnings • Mar 01Full year 2023 earnings releasedFull year 2023 results: Revenue: €757.6m (down 26% from FY 2022). Net income: €28.8m (down 59% from FY 2022). Profit margin: 3.8% (down from 6.9% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 3.3% decline forecast for the Chemicals industry in the United Kingdom.
お知らせ • Dec 01+ 2 more updatesErcros, S.A. to Report Q3, 2024 Results on Nov 15, 2024Ercros, S.A. announced that they will report Q3, 2024 results on Nov 15, 2024
Valuation Update With 7 Day Price Move • Nov 13Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €2.47, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 19x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €2.39 per share.
New Risk • Nov 08New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.8% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (4.2% net profit margin).
お知らせ • Oct 18Ercros, S.A. to Report Q3, 2023 Results on Nov 08, 2023Ercros, S.A. announced that they will report Q3, 2023 results on Nov 08, 2023
New Risk • Jul 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.2% Last year net profit margin: 8.3% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (4.2% net profit margin).
Reported Earnings • Jul 27Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €222.4m (down 22% from 2Q 2022). Net income: €3.81m (down 87% from 2Q 2022). Profit margin: 1.7% (down from 10% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is expected to fall by 1.4% p.a. on average during the next 3 years compared to a 6.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.
Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. Proprietary Director Joan Galofre was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 23+ 1 more updateErcros, S.A. to Report First Half, 2023 Results on Aug 31, 2023Ercros, S.A. announced that they will report first half, 2023 results on Aug 31, 2023
Upcoming Dividend • Jun 19Upcoming dividend of €0.12 per share at 4.8% yieldEligible shareholders must have bought the stock before 26 June 2023. Payment date: 28 June 2023. Payout ratio is a comfortable 21% and this is well supported by cash flows. Trailing yield: 4.8%. Lower than top quartile of British dividend payers (5.9%). Higher than average of industry peers (2.7%).
お知らせ • May 04Ercros, S.A., Annual General Meeting, Jun 15, 2023Ercros, S.A., Annual General Meeting, Jun 15, 2023, at 12:00 Central European Standard Time. Location: Uría Menéndez Auditorium, Avenida Diagonal 514, 6th floor Barcelona Spain Agenda: To consider financial statements and directors' report; to consider statement of non-financial information of the Company and its consolidated Group for the year ended 31 December 2022; to consider Re-election of Ernst & Young, S.L. as the auditor.
Buying Opportunity • May 03Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 2.6%. The fair value is estimated to be €4.62, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 48%. For the next 3 years, revenue is forecast to decline by 5.4% per annum. Earnings is also forecast to decline by 12% per annum over the same time period.
Reported Earnings • Feb 24Full year 2022 earnings released: EPS: €0.64 (vs €0.43 in FY 2021)Full year 2022 results: EPS: €0.64 (up from €0.43 in FY 2021). Revenue: €1.02b (up 28% from FY 2021). Net income: €70.6m (up 63% from FY 2021). Profit margin: 6.9% (up from 5.4% in FY 2021). The increase in margin was driven by higher revenue. Revenue is expected to decline by 8.9% p.a. on average during the next 2 years, while revenues in the Chemicals industry in the United Kingdom are expected to grow by 1.7%. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 30Ercros, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023Ercros, S.A. announced that they will report fiscal year 2022 results on Feb 28, 2023
Buying Opportunity • Nov 16Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 7.3%. The fair value is estimated to be €3.97, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 36%. Revenue is forecast to decline by 13% in 2 years. Earnings is forecast to decline by 40% in the next 2 years.
Buying Opportunity • Nov 10Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 4.2%. The fair value is estimated to be €4.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 36%. Revenue is forecast to decline by 13% in 2 years. Earnings is forecast to decline by 40% in the next 2 years.
Reported Earnings • Jul 30Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €297.7m (up 50% from 2Q 2021). Net income: €29.1m (up 152% from 2Q 2021). Profit margin: 9.8% (up from 5.8% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is expected to shrink by 3.5% compared to a 15% decline forecast for the industry in the United Kingdom.
Buying Opportunity • Jul 28Now 21% undervaluedOver the last 90 days, the stock is up 11%. The fair value is estimated to be €4.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.9% over the last 3 years. Earnings per share has grown by 26%. Revenue is forecast to decline by 5.0% in 2 years. Earnings is forecast to decline by 3.9% in the next 2 years.
Buying Opportunity • Jul 01Now 21% undervaluedOver the last 90 days, the stock is up 20%. The fair value is estimated to be €4.64, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.9% over the last 3 years. Earnings per share has grown by 26%. Revenue is forecast to decline by 5.0% in 2 years. Earnings is forecast to decline by 3.9% in the next 2 years.
Upcoming Dividend • Jun 13Upcoming dividend of €0.069 per shareEligible shareholders must have bought the stock before 20 June 2022. Payment date: 22 June 2022. Trailing yield: 2.4%. Lower than top quartile of British dividend payers (4.9%). Lower than average of industry peers (3.0%).
Buying Opportunity • May 06Now 20% undervaluedOver the last 90 days, the stock is up 9.1%. The fair value is estimated to be €4.15, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 6.1%. Revenue is forecast to decline by 7.5% in 2 years. Earnings is forecast to decline by 13% in the next 2 years.
Buying Opportunity • Mar 23Now 21% undervaluedOver the last 90 days, the stock is up 1.8%. The fair value is estimated to be €3.88, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 6.1% per annum over the last 3 years.
Buying Opportunity • Mar 03Now 22% undervaluedOver the last 90 days, the stock is up 8.9%. The fair value is estimated to be €3.97, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 6.1% per annum over the last 3 years.
Reported Earnings • Nov 14Third quarter 2021 earnings releasedThe company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €210.9m (up 56% from 3Q 2020). Net income: €5.90m (up €5.70m from 3Q 2020). Profit margin: 2.8% (up from 0.1% in 3Q 2020). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • May 10Investor sentiment improved over the past weekAfter last week's 16% share price gain to €3.12, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 26x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 24% over the past three years.
Reported Earnings • Mar 02Full year 2020 earnings released: EPS €0.061 (vs €0.29 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €585.3m (down 13% from FY 2019). Net income: €6.26m (down 80% from FY 2019). Profit margin: 1.1% (down from 4.6% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
Analyst Estimate Surprise Post Earnings • Mar 02Revenue beats expectationsRevenue exceeded analyst estimates by 3.0%. Over the next year, revenue is forecast to grow 5.8% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom.
Is New 90 Day High Low • Feb 16New 90-day high: €2.51The company is up 18% from its price of €2.14 on 17 November 2020. The British market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period.
Valuation Update With 7 Day Price Move • Nov 26Market bids up stock over the past weekAfter last week's 15% share price gain to €2.39, the stock is trading at a trailing P/E ratio of 10.2x, up from the previous P/E ratio of 8.8x. This compares to an average P/E of 37x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years were flat.
Is New 90 Day High Low • Nov 24New 90-day high: €2.19The company is up 6.0% from its price of €2.07 on 25 August 2020. The British market is also up 6.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Chemicals industry, which is up 5.0% over the same period.
Is New 90 Day High Low • Nov 02New 90-day low: €1.75The company is down 5.0% from its price of €1.84 on 04 August 2020. The British market is down 6.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 2.0% over the same period.
